Comparison of DNA Methylation Changes Between the Gestation Period and the After-Delivery State: A Pilot Study of 10 Women

Ming-Wei Lin¹, Mong-Hsun Tsai²,³, Ching-Yu Shih², Yi-Yun Tai⁴, Chien-Nan Lee¹ and Shin-Yu Lin*¹

¹ Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, ² Bioinformatics and Biostatistics Core Lab, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan, ³ Institute of Biotechnology, National Taiwan University, Taipei, Taiwan, ⁴ Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan

Background: Gestational adaptation occurs soon after fertilization and continues throughout pregnancy, whereas women return to a pre-pregnancy state after delivery and lactation. However, little is known about the role of DNA methylation in fine-tuning maternal physiology. Understanding the changes in DNA methylation during pregnancy is the first step in clarifying the association of diet, nutrition, and thromboembolism with the changes in DNA methylation. In this study, we investigated whether and how the DNA methylation pattern changes in the three trimesters and after delivery in ten uncomplicated pregnancies.

Results: DNA methylation was measured using a Human MethylationEPIC BeadChip. There were 14,018 cytosine-guanine dinucleotide (CpG) sites with statistically significant changes in DNA methylation over the four time periods (p < 0.001). Overall, DNA methylation after delivery was higher than that of the three trimesters (p < 0.001), with the protein ubiquitination pathway being the top canonical pathway involved. We classified the CpG sites into nine groups according to the changes in the three trimesters and found that 38.37% of CpG sites had DNA methylation changes during pregnancy, especially between the first and second trimesters.

Conclusion: DNA methylation pattern changes between trimesters, indicating possible involvement in maternal adaptation to pregnancy. Meanwhile, DNA methylation patterns during pregnancy and in the postpartum period were different, implying that puerperium repair may also function through DNA methylation mechanisms.

Keywords: DNA methylation, gestational adaptation, pregnancy, pathway analysis, after-pregnancy status

INTRODUCTION

Gestational adaptation occurs soon after fertilization and continues throughout pregnancy, while women return to a pre-pregnancy state after delivery and lactation. Almost every organ system undergoes important physiological alterations and adaptations that support fetal development and help the mother and fetus survive the demands of childbirth (1). For example, plasma volume
and total red cell mass are controlled by different mechanisms, and pregnancy provides the most dramatic example of how this can occur (2). Moreover, the maintenance of pregnancy relies on finely tuned immune adaptations (3). These immunological changes increase fetal survival and permit accommodation of the semi-allogeneic fetal graft (4). Since physiological adaptations during pregnancy are crucial for the developing fetus and the demands of childbirth, understanding these changes is important to recognize pathological deviations in obstetric complications and to optimize the outcomes for both the mother and her baby.

There is growing evidence that epigenetic mechanisms (DNA methylation, histone modification, and non-coding RNAs) are responsible for tissue-specific gene expression during growth and development and that these mechanisms underlie developmental plasticity (5). Such tuning of phenotypes has potential adaptive value and Darwinian fitness advantage because it attempts to produce a phenotype optimized for current circumstances or the predicted future environment (6). Maternal caloric malnutrition or an imbalanced diet with low protein can lead to changes in DNA methylation and fetal programming, making the offspring more resilient to future stress (7). However, the nuances of changes in DNA methylation and the transcriptional control of gene expression are not completely understood. An increasing number of studies are investigating obstetric complications such as gestational diabetes, preterm birth, and preeclampsia through epigenetic mechanism (8–13). Nevertheless, most studies have focused on epigenetic changes in the placenta or cord blood instead of maternal blood. In addition, little is known about how DNA methylation changes during gestation. Variation in DNA methylation before and throughout pregnancy was first described by Pauwels et al. (14). They noted that the mean global DNA methylation percentage was significantly higher before pregnancy than during pregnancy. Chen et al. later investigated methylation dynamics in women from preadolescence to late pregnancy (15). Nevertheless, the present study used different female cohorts to show the methylation dynamics before and after pregnancy. Several studies have investigated epigenetic markers in the maternal peripheral blood for obstetric complications (16–21). However, the effect of gestational age on DNA methylation profiles remains unknown. Pregnancy DNA methylation profiling in a healthy population may provide a basis for improving our understanding of the development of pregnancy complications. Therefore, our aim was to study DNA methylation changes in different trimesters and its status after delivery and to describe the DNA methylation patterns in different physiological pathways.

**MATERIALS AND METHODS**

Ten women with uncomplicated pregnancies were enrolled. The inclusion criteria were pregnant women who visited our hospital before the 14th week of gestation and were willing to participate in the study. The exclusion criteria were pregnant women with underlying medical conditions, including but not limited to any infection symptoms or signs, autoimmune disorders, abnormal thyroid function, asthma, urticaria, thalassemia carrier, abnormal kidney function, and any other conditions that may affect DNA methylation. The patients were divided into three groups based on gestational age: the first trimester (11–13 weeks), the second trimester (14–27 weeks), and the third trimester (28–40 weeks). DNA methylation was measured using bisulfite sequencing. The DNA methylation patterns were analyzed using the statistical software R.

**TABLE 1** The nine groups with different methylation patterns in the three trimesters.

| Group | β value of 1st trimester–β value of 2nd trimester | β value of 2nd trimester–β value of 3rd trimester | N (%) of CpG sites | Illustration |
|-------|-----------------------------------------------|-----------------------------------------------|--------------------|-------------|
| 1     | <−0.02                                        | −0.02                                        | 43 (0.31%)         |            |
| 2     | >0.02                                         | >0.02                                        | 39 (0.28%)         |            |
| 3     | <−0.02                                        | >0.02                                        | 9 (0.06%)          |            |
| 4     | >0.02                                         | <−0.02                                       | 117 (0.83%)        |            |
| 5     | Between −0.02 and 0.02                        | <−0.02                                       | 513 (3.66%)        |            |
| 6     | Between −0.02 and 0.02                        | >0.02                                        | 48 (0.34%)         |            |
| 7     | <−0.02                                        | Between −0.02 and 0.02                       | 995 (7.10%)        |            |
| 8     | >0.02                                         | Between −0.02 and 0.02                       | 3,173 (22.64%)     |            |
| 9     | Between −0.02 and 0.02                        | Between −0.02 and 0.02                       | 8,639 (61.63%)     |            |

These groups are classified according to the differences of the average β values between the first and the second trimesters, as well as that between the second and the third trimesters.
Isolation of Genomic DNA, Bisulfite Conversion, DNA Amplification, Fragmentation, and Hybridization of Illumina Infinium® Methylation Array

Genomic DNA was extracted using a QIAamp DNA Micro Kit (Qiagen). Genomic DNA was isolated using proteinase K-phenol-chloroform extraction following standard protocols with 0.5% sodium dodecyl sulfate and 200 μg/mL proteinase K. Normalized DNA concentrations of 50 ng/μL and total genomic DNA (500 ng) were used for DNA bisulfite conversion using the EZ DNA Methylation™ kit (Zymo Research). Bisulfite-treated DNA (200 ng) was used in the Infinium MethylationEPIC assay. First, the bisulfite-treated DNA was amplified by DNA polymerase during the incubation step in the Illumina hybridization oven for 20–24 h at 37°C. The amplified DNA product was fragmented into 300–600 base pairs. After alcohol precipitation and re-suspension of the fragmented DNA, the BeadChip was prepared for hybridization in the capillary flow-through chamber (Illumina Human MethylationEPIC BeadChip Array, Illumina) Each array accommodated eight samples, and the plate layout is listed in Supplementary Table 1. The amplified and fragmented DNA samples were annealed to locus-specific 50-mers during the hybridization step at 48°C for 16 h in an Illumina Hybridization Oven. After hybridization, allele specificity was determined using an enzymatic single-base extension. The products were then fluorescently stained with biotin-ddNTPs or dinitrophenol-ddNTPs. The intensity of the bead fluorescence was measured using Illumina HiScan (iScan Control Software v3.3.28), and the results were analyzed using GenomeStudio Software v2011.1 for methylation profiles.

Statistical Analysis

Before data analysis, we used data from the first trimester for normalization for each woman. Principal component analysis (PCA) was also performed to exclude batch effects (Supplementary Figure 1). Differential DNA methylation analysis was conducted using R software (version 3.6.3). Methylation levels (β values) were obtained from the microarray data, where the β value is the ratio of the methylated probe intensity to the overall intensity. The β values were transformed into the corresponding M values by log transformation, and differential methylation analysis was conducted (22). One-way ANOVA was used to identify differentially methylated cytosine-guanine dinucleotide (CpG) sites during the four time periods. CpG sites with probe SNPs within 10 base pairs (bp) were deleted. We also removed CpG probes with p > 0.01 in one sample. Only probes with a significant difference in the average β value over the four time periods (p < 0.001) were selected for further analysis (n = 14,018). Average delta-beta values indicating differentially methylated CpG sites were

| TABLE 2 | Clinical characteristics in the pregnant women included in this study. |
|---------|------------------|
| Baseline characteristics   | All             |
| N         | 10              |
| Age (years)  | 33.2 (4.5)     |
| Nulliparous (N, %)   | 6 (60%)         |
| Gestational age at the FPV (weeks) | 10 (2.5)       |
| Family history of DM (N, %)  | 5 (50%)         |
| Pre-pregnancy BW (Kg)   | 53 (4.2)        |
| Pre-pregnancy BMI (kg/m²) | 21.5 (2.2)     |
| SBP (mmHg)    | 105.4 (9.6)     |
| DBP (mmHg)    | 61.1 (9.1)      |
| **Laboratory test results at the first prenatal visit** |
| Hb (g/dl)   | 12.6 (1.2)      |
| WBC (K/µL)  | 7.9 (1.4)       |
| TC (mg/dl)  | 184 (36.3)      |
| LDL-C (mg/dl) | 99 (26.1)     |
| HDL-C (mg/dl) | 73.1 (11.3)  |
| TG (mg/dl)  | 102.6 (46.2)    |
| FPG (mg/dl) | 81.2 (4.1)      |
| HbA1c (%)   | 5.2 (0.3)       |
| GWG at 24–28 gestational weeks (kg) | 3.7 (3.4) |

**Laboratory test results at 24-28 gestational weeks**

| Glucose level during OGTT at 24-28 gestational weeks |
|---------------------------------------------------|
| FPG during OGTT (mg/dl) | 76.7 (2.4) |
| 1hPG (mg/dl)             | 122.4 (19.9) |
| 2hPG (mg/dl)             | 105.5 (23.3) |
| GWG at delivery (kg)     | 6.9 (4.5)   |

**Laboratory test results at delivery**

| Birth weight (g) | 2961.3 (347.1) |

Mean (standard deviations) or N (%) were shown. BMI, body mass index; BW, body weight; DBP, diastolic blood pressure; DM, diabetes mellitus; FPG, fasting plasma glucose; FPV, first prenatal visit; GWG, gestational weight gain, compared to the body weight before pregnancy; Hb, hemoglobin; HbA1c, hemoglobin A1c; glycated hemoglobin; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; OGTT, oral glucose tolerance tests; FPG during OGTT, fasting plasma glucose during oral glucose tolerance tests; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WBC, white blood cell; 1hPG, 1-hour plasma glucose during oral glucose tolerance tests; 2hPG, 2-hour plasma glucose during oral glucose tolerance tests.
used with different cut-offs to classify the data into nine categories from the three trimesters. The details are presented in Table 1. We considered a difference in methylation > 2%—that is, at least one CpG site within the designated region must have a mean difference in methylation of >2% between samples among the three trimesters (Δβ = 0.02)—to be of biological interest. Furthermore, gene ontology and pathway analyses were conducted using Ingenuity Pathway Analysis (IPA®; Qiagen, Redwood City, CA) on (1) the top 1,000 significant differentially methylated CpG sites over the four groups (time periods) (p < 0.001) and (2) the significant findings (p < 0.001) from the nine groups. The heat map was produced using the pheatmap package (version 1.0.12) in R.

RESULTS

The demographic characteristics are shown in Table 2. Among the 865,918 CpG sites, 14,018 showed statistically significant differences in methylation between the four time periods (P < 0.001). The heat map illustrates the top 1,000 CpG sites with significant methylation differences during the four periods (Figure 1). The mean DNA methylation level was higher after delivery than in the three trimesters (P < 0.001) (Figure 2).

IPA of the 14,018 CpG sites revealed that the top five canonical pathways were the “protein ubiquitination pathway”, followed by “hypoxia signaling in the cardiovascular system”, “inhibition of ARE-mediated mRNA degradation pathway”, “tumor necrosis factor receptor (TNFR)2 signaling,” and “phagosome maturation” (Table 3). The top five physiological systems were “embryonic development,” followed by “hematologic system development and function,” “humoral immune response,” “immune cell trafficking,” and “organ morphology.”

We classified the 14,018 CpG sites into nine groups according to changes in the three trimesters (Table 1; Figure 3; Supplementary Tables 2–10). Group 1: The β values increased with time (N = 43, 0.31%). Group 2: The β values decreased with time (N = 39, 0.28%). Group 3: The β values rose and then fell (N = 9, 0.06%). Group 4: The β values decreased before increasing (N = 117, 0.83%). Group 5: The β values remained the same in the first two trimesters and then increased in the third trimester (N = 513, 3.66%). Group 6: The β values remained the same in the first two trimesters and then decreased in the third trimester (N = 48, 0.34%). Group 7: The β values increased from the first trimester to the second trimester and remained the same between
FIGURE 2 | The mean β value of the top 1,000 CpG sites with significant methylation differences within the 1st trimester, 2nd trimester, 3rd trimester and after-delivery status (p < 0.001). Y-axis denotes DNA methylation intensity shown by mean β value; X-axis denotes biosampling occasions. *p < 0.001.

TABLE 3 | The ingenuity pathway analysis for the top 1,000 CpG sites with statistically significant mean β value difference within the 1st trimester, 2nd trimester, 3rd trimester, and after-delivery status.

| Name                                      | P-value | Genes                                                                 |
|-------------------------------------------|---------|-----------------------------------------------------------------------|
| The top five canonical pathways            |         |                                                                        |
| Protein ubiquitination pathway             | 2.41E-11| UBE2D1, UBE2E1, UBE2F, UBE2H, UBE2J2, UBE2K, UBE2L, UBE2O, UBE2Q2, UBE2V1, UBE3A, UCHL3, USP1, USP12, USP22, USP35, USP36, USP40, USP42, USP45, USP48, USP54, USP8, ZBTB12 |
| Hypoxia signaling in the cardiovascular system | 1.41E-06| UBE2D1, UBE2E1, UBE2F, UBE2H, UBE2J2, UBE2K, UBE2L, UBE2O, UBE2Q2, UBE2V1 |
| Inhibition of ARE-mediated mRNA degradation pathway | 5.57E-04| TNF, TNFRSF1A, TNFRSF1B, TNFRSF10, TNFRSF13, YWHAG, YWHAQ, ZFP36, ZFP36L1 |
| TNFR2 signaling                           | 9.18E-04| TNF, TNFAIP3, TNFRSF1B, TRAF1                                          |
| Phagosome maturation                      | 1.43E-03| TUBA1B, TUBB, VAMP2, VPS28, VPS37B, VT11A, YKT6, ZBTB12               |

DISCUSSION

In this study, we focused on investigating changes in DNA methylation during each trimester and after delivery. The findings provided supporting evidence that changes in DNA methylation during pregnancy may be important for maternal adaptation to pregnancy. Meanwhile, DNA methylation patterns during and after pregnancy were different, implying that puerperium repair may also act through DNA methylation mechanisms. In addition, different patterns of DNA methylation between the trimesters were identified in the present study. Therefore, based on our findings, studies related to DNA methylation during pregnancy should specify the time when the samples were obtained because gestational age is important for interpreting the results.

According to the IPA of the 14,018 identified CpG sites, the top canonical pathway involved is the "protein ubiquitination pathway," which is a reversible process due to the presence of deubiquitinating enzymes that can cleave ubiquitin from modified proteins (Table 3) (23). Protein ubiquitination is essential for normal placental growth and development (24). In addition, the epigenetic regulatory role of long non-coding RNAs in the ubiquitin proteasome system and collagen remodeling may be related to spontaneous preterm labor and preterm premature rupture of membranes (25–27). TNFR2 signaling was also determined using IPA. TNF-α is also associated with inflammatory mechanisms related to implantation, placentation, and pregnancy outcomes. TNF-α is secreted by immune cells
and binds TNFR1 and TNFR2. Elevated TNF-α is associated with recurrent pregnancy loss, early and severe preeclampsia, and recurrent implantation failure; all of these are “idiopathic” or related to antiphospholipid positivity, which implies the important role of TNF-α in maintaining normal pregnancy (28).

In this study, most CpG sites were in Group 9 (N = 8,639, 61.63%), indicating that although DNA methylation changes during pregnancy and after delivery, most of these changes were subtle during pregnancy. In Group 9, DNA methylation increased slightly after delivery. In addition, there were 4,168 (29.73%) CpG sites in Group 7 (995, 7.1%) and Group 8 (3,173, 22.64%), and significant DNA methylation changes were observed between the first and second trimesters. This is the stage of embryonic development and organogenesis (29). The results of the IPA of Groups 7 and 8 in the present study provided supporting evidence that hematologic system development and function, tissue development, tissue morphology, and hematopoiesis were the top systems and functions involved in the pregnancy. Some of these systems and functions overlap with those of Groups 1, 2, 4, and 6. In contrast, the IPA of Group 5 yielded very different results. The top five systems and functions involved were nervous system development and function, embryonic development, hair and skin development and function, humoral immune response, and urinary system development and function. Since Group 5 had a significant increase in DNA methylation between the second and third trimesters, further studies are needed to investigate the functional implications of DNA methylation changes during this period and the development and functions of these systems. The IPA results of canonical pathways involved in different groups are quite diverse. Pathways involved in glucose homeostasis were found in Groups 1, 2, 4, 6, and 8, whereas those involved in the immune system were identified in Groups 5, 6, 7, and 8. These findings suggested that changes in glucose homeostasis and the immune system during pregnancy are at least partly mediated by DNA methylation mechanisms. For example, our previous study showed that many genes had different methylation patterns in gestational diabetes mellitus (GDM) and non-GDM groups (18). In addition, hypomethylation of IL-10 in maternal blood and increased plasma concentrations of IL-10 before delivery were noted in women with gestational diabetes (30). A number of publications have identified the mechanisms through which...
TABLE 4 | The Ingenuity pathway analysis of each group for the top 5 physiological system development and function within 3 trimesters and after delivery.

| Name | P-value range |
|------|---------------|
| **Group 1 and 2 (82 CpG sites)** | |
| Hematological system development and function | 4.60E-02–8.11E-04 |
| Nervous system development and function | 6.96E-03–8.11E-04 |
| Tissue development | 6.90E-02–8.11E-04 |
| Tissue morphology | 2.25E-02–8.11E-04 |
| Organismal functions | 1.86E-02–1.86E-02 |
| **Group 4 (117 CpG sites)** | |
| Cardiovascular system development and function | 2.96E-02–8.03E-04 |
| Cell-mediated immune response | 1.50E-03–1.50E-03 |
| Hematologic system development and function | 7.47E-03–1.50E-03 |
| Immune cell trafficking | 1.50E-03–1.50E-03 |
| Lymphoid tissue structure and development | 1.50E-03–1.50E-03 |
| **Group 5 (513 CpG sites)** | |
| Nervous system development and function | 6.67E-03–4.36E-04 |
| Embryonic development | 1.33E-02–2.79E-03 |
| Hair and skin development and function | 2.79E-03–2.79E-03 |
| Humoral immune response | 1.33E-02–4.99E-03 |
| Renal and urological system development and function | 1.33E-02–4.99E-03 |
| **Group 6 (48 CpG sites)** | |
| Hematological system development and function | 4.22E-02–4.40E-05 |
| Humoral immune response | 3.52E-02–4.40E-05 |
| Immune cell trafficking | 4.22E-02–4.40E-05 |
| Tissue morphology | 8.19E-03–9.67E-04 |
| Embryonic development | 3.94E-02–2.42E-03 |
| **Group 7 (995 CpG sites)** | |
| Hematological system development and function | 1.46E-03–1.17E-07 |
| Lymphoid tissue structure and development | 1.46E-03–1.17E-07 |
| Hematopoiesis | 1.02E-03–8.06E-07 |
| Tissue development | 1.30E-03–8.06E-07 |
| Embryonic development | 7.41E-04–1.28E-06 |
| **Group 8 (3,173 CpG sites)** | |
| Hematological system development and function | 6.74E-03–2.49E-06 |
| Immune cell trafficking | 6.74E-03–2.49E-06 |
| Tissue development | 4.12E-03–1.28E-05 |
| Tissue morphology | 7.12E-04–9.28E-05 |
| Hematopoiesis | 3.84E-03–1.62E-04 |
| **Group 9 (8,639 CpG sites)** | |
| Tissue development | 6.04E-04–1.21E-07 |
| Hair and skin development and function | 2.88E-05–2.88E-05 |
| Hematological system development and function | 6.04E-04–8.76E-05 |
| Organismal development | 6.04E-04–1.94E-04 |
| Connective tissue development and function | 2.01E-04–1.98E-04 |

Maternal nutrition and environmental exposures, such as stress and toxic substances that alter the expression of imprinted genes during pregnancy, can influence fetal and neonatal phenotypes and susceptibility to disease development later in life (31–33). Understanding how maternal epigenomes change during different trimesters may help to investigate the pathophysiology of obstetric and fetal complications.

Pauwels et al. noted that the mean global DNA methylation percentage before pregnancy (6.89%) was significantly higher than that at 12 weeks (6.24%; \( p = 0.007 \)), 30 weeks (6.36%; \( p = 0.04 \)), and after delivery (6.35%; \( p = 0.04 \) (14). Gruziev et al. also demonstrated that most CpG sites show a decrease in average methylation levels before, during, and immediately after pregnancy (34). In this study, the mean methylation degree of the top 1,000 CpG sites with significant changes was the highest in the postpartum period (mean \( \beta \) value = 0.432), followed by those in the first trimester (mean GA at 10 weeks, mean \( \beta \) value = 0.346, \( p < 0.001 \)), second trimester (mean GA at 25 weeks, mean \( \beta \) value = 0.338, \( p < 0.001 \)), and third trimester (mean GA at 38 weeks, mean \( \beta \) value = 0.338, \( p < 0.001 \)). White et al. analyzed genome-wide differential methylation patterns in maternal leukocyte DNA in early pregnancy (\( n = 14 \)), in the same women postpartum (\( n = 14 \)), and age- and body mass index (BMI)-matched nulligravid women (\( n = 14 \)) (35). White et al. identified 264 significant CpG sites, 122 (46.2%) of which were significantly different in this study (Supplementary Table 11). They identified nine genes with at least one CpG site differentially methylated in early pregnancy compared to both non-pregnancy groups (nulligravid and postpartum), which were significant at the 10% FDR (false discovery rate) level (q < 0.10). Seven of the nine genes (NFE2L2, IL1R2, PTPRJ, SPAG4, HPR, CCIN, and PC) were also differentially methylated between the mean \( \beta \) value of the three trimesters and the value after delivery in this study (\( p < 0.005 \)). All seven genes showed more hypomethylation during pregnancy than after delivery, which was in agreement with White’s findings. All studies showed that the degree of DNA methylation was much higher after delivery than that during pregnancy. These findings agree with the concept that more genes are expressed during pregnancy for maternal changes and adaptation than after delivery. The findings of the present study suggested that puerperium repair may occur through DNA methylation mechanisms.

In the Born into Life study (36), Gruziev et al. measured epigenome-wide DNA methylation in 34 women on four occasions: once before, twice during, and once 2–4 days after pregnancy (34). They identified 196 significant CpG sites, 133 (67.9%) of which showed significant methylation differences in this study (Supplementary Table 12). We compared the data from this study with the dataset GSE37722 from White et al. and the dataset GSE122408 from Gruzieva et al. There was one significant overlapping CpG site (cg24621042) in the SERPINA1 gene, which was less methylated during pregnancy than during the non-pregnancy period in all three datasets. SERPINA1 provides instructions for producing a protein called alpha-1 antitrypsin, which is a serine protease inhibitor (serpin). Serpins help to control several types of chemical reactions by inhibiting the activity of certain enzymes. This warrants further investigation of the physiological significance of hypomethylation in SERPINA1 during pregnancy.

Pregnancy is an acquired risk factor of venous thromboembolism (VTE) (37). In 2020, Wang et al. first demonstrated that blood-based global DNA methylation is
| Name | P-value | Genes |
|------|---------|-------|
| **Group 1 and 2 (82 CpG sites)** | | |
| Insulin secreting signaling pathway | 1.17E-03 | ITPR1,PRKAG2,VTI1A |
| Netrin signaling | 1.53E-03 | ITPR1,PRKAG2 |
| GRCR-mediated integration of enteroendocrine signaling exemplified by an L cell | 1.53E-03 | ITPR1,PRKAG2 |
| Synaptogenesis signaling pathway | 1.82E-03 | ITPR1,PRKAG2,VTI1A |
| Neuropathic pain signaling in dorsal horn neurons | 2.92E-03 | ITPR1,PRKAG2 |
| **Group 4 (117 CpG sites)** | | |
| Maturity onset diabetes of young (MODY) signaling | 3.53E-03 | CACNA1A,OGDH |
| 2-ketoglutarate dehydrogenase complex | 5.98E-03 | OGDH |
| CDK5 signaling | 1.12E-02 | CACNA1A,PPP2R2A |
| Cardiac-adrenergic signaling | 1.86E-02 | CACNA1A,PPP2R2A |
| Dopamine-DARPP32 feedback in cAMP signaling | 2.36E-02 | CACNA1A,PPP2R2A |
| **Group 5 (513 CpG sites)** | | |
| Nitric oxide signaling in the cardiovascular system | 3.99E-05 | AKT2,ATP2A3,GUCY2D,ITPR1,MAPK1,PRKCZ |
| Apelin cardiomyocyte signaling pathway | 5.04E-05 | AKT2,ATP2A3,ITPR1,MAPK1,PRKCZ,SLC9A8 |
| Phospholipase C signaling | 5.51E-05 | AHNAK,CREB3L3,ITPR1,MAPK1,MRPIP,NFAT1,PRKCZ,RHOA,ZAP70 |
| NGF signaling | 1.12E-04 | AKT2,CREB3L3,MAPK1,PRKCZ,RHOA,RPS6KA2 |
| IL-7 signaling pathway | 1.29E-04 | AKT2,CXCR5,MAPK1,MLC1,NFAT1 |
| **Group 6 (48 CpG sites)** | | |
| Ceramide signaling | 7.88E-04 | PIK3CD,TNFRSF1B |
| PD-1, PD-L1 cancer immunotherapy pathway | 1.08E-03 | PIK3CD,TNFRSF1B |
| IL-6 signaling | 1.61E-03 | PIK3CD,TNFRSF1B |
| Type II diabetes mellitus signaling | 1.96E-03 | PIK3CD,TNFRSF1B |
| HMGB1 signaling | 2.48E-03 | PIK3CD,TNFRSF1B |
| **Group 7 (995 CpG sites)** | | |
| T helper cell differentiation | 3.05E-05 | IFNG,IL21,IL5,IL6ST,TNF |
| Cardiac hypertrophy signaling (enhanced) | 9.33E-05 | EP300,FGFR1,GNG7,HDAC3,IFNG,IL21,IL5,IL6ST,ITGB2,LEP,PLCH1,PTK2,TNF |
| Hepatic fibrosis/hepatic stellate cell activation | 1.99E-04 | BCL2,COL2A1,COL5A1,FGFR1,IFNG,LEP,MYH10,TNF |
| IL-7 signaling pathway | 4.40E-04 | BCL2,FYN,IFNG,IL7R,PTK2 |
| Systemic lupus erythematosus in B cell signaling pathway | 5.42E-04 | BCL2,FYN,IFNG,IL21,IL5,IL6ST,LEP,SYK,TNF |
| **Group 8 (3,173 CpG sites)** | | |
| TREM1 signaling | 5.41E-04 | IL18,MPO,NLPP3,NOD1,STAT5A,TLR5,TLR6,TREM1 |
| Fcγ receptor-mediated phagocytosis in macrophages and monocytes | 8.49E-04 | FYB1,INPP5D,LYN,NCK1,NCK2,PRKCE,PRKCZ,SRC,VAV2 |
| IL-15 production | 1.25E-03 | AATK,DSTYK,FES,IGF1R,LYN,MAP2K6,PRKCZ,SRC,STAT1,TNK2 |
| Insulin secretion signaling pathway | 2.00E-03 | AG01,AG02,AG03,CACNA1C,CHRM3,EIF4G3,ITPR1,KL1,LYN,PRKCE,PRKCZ,SCNN1A,SRC,STAT1,ST5A |
| Molecular mechanisms of cancer | 2.17E-03 | ARHGEF10,ARHGEF17,AXIN1,BMP1,CCND2,CTNND1,DAXX,ERF3,ENA12,HHAT,HIPK2,ITGA6,MAP2K6,NOTCH1,PRKCE,PRKCZ,RB1,SHC1,SRC,SYNGAP1,TFDP1 |
| **Group 9 (8,639 CpG sites)** | | |
| Molecular mechanisms of cancer | 3.12E-08 | ABL1,AKT1,APC,ARHGEF10,ARHGEF15,ARHGEF18,ARHGEF17,AXIN1,BMP6,CAMK2D,CASP8,CCND1,CCND2,CDK5,CDK6,CREBBP,CTNNB1,DAXX,DIABLO, |
TABLE 5 | Continued

| Name | P-value | Genes |
|------|---------|-------|
| DIRAS3,E2F2,E2F5,FNBP1,FYN,FZD2,FZD6, FZD8,GAB1,GNA13,GNAO1,GNA1,T1R1,GRB2,ITGA6, ITGA7,JAK1,JAK3,KRAS,LRPs3,MAP2K3,MAPK1, MYC,NAIP,NF1,NFkB1,NOTCH1,PAK4, PIK3C2B,PIK3CD,PIK3R2,PIK3R5,PRKAG2, PRKAI1B,PRKCE,PRKCI,PRKCZ,PRKD3, PSEN1,RAF1,RALB,RAP1B,RAPGEF1,RASGRF1, RBPJ,RHOB,B2,RHO,G,SMAD3,SMAD4,SMAD7, TCF3,TGFBR1,WNT4,WNT5B,WNT7A | 0.0479 | IL-7 signaling pathway |
| AKT1,BCL6,CCND1,CXCR5,EBF1,FOSX3,MYC, NFATC1,PDPK1,PIK3CD,PIK3R2, PIK3R5,SLC2A1,STAT1,STAT5B | 0.0000 | Glioblastoma multiforme signaling |
| 0.0000 | AKT1,E2F2,E2F5,FNBP1,FYN,FZD2,FZD6, FZD8,GAB1,GNA13,GNAO1,GNA1,T1R1,GRB2,ITGA6, ITGA7,JAK1,JAK3,KRAS,LRPs3,MAP2K3,MAPK1, MYC,NAIP,NF1,NFkB1,NOTCH1,PAK4, PIK3C2B,PIK3CD,PIK3R2,PIK3R5,PRKAG2, PRKAI1B,PRKCE,PRKCI,PRKCZ,PRKD3, PSEN1,RAF1,RALB,RAP1B,RAPGEF1,RASGRF1, RBPJ,RHOB,B2,RHO,G,SMAD3,SMAD4,SMAD7, TCF3,TGFBR1,WNT4,WNT5B,WNT7A | 0.0000 | c Epsilon RI signaling |
| AKT1,E2F2,E2F5,FNBP1,FYN,GAB1,GRAP2, GRB2,INPP5J,INPP5K,KRAS,LAT1,LYN,MAP2K3, MAPK1,MSA42,PDPK1,PIK3C2B,PIK3CD,PIK3R2, PIK3R5,PLA2G4F,PLA2G6,PRKCE,PRKCI,PRKCZ, PRKCD,RAF1,RALB,RAP1B,SYNJ2,TNF | 0.0000 | Regulation of the epithelial-mesenchymal transition pathway |

associated with venous thromboembolism (38). Global DNA methylation was significantly higher in patients with primary VTE than in healthy controls (median: 0.17 vs. 0.08%; \( p < 0.001 \)). We also noted that global DNA methylation was significantly higher in pregnant patients than in postpartum patients (\( p < 0.001 \)). VTE is a multifactorial disease influenced by both genetic and non-genetic risk factors (39). Epigenetic factors may play a role in VTE pathophysiology. Several genes in coagulation pathways, including genes for von Willebrand factors, factor VII, and factor VIII, are regulated by DNA methylation (40–42). Further studies are required to investigate the mechanisms underlying the role of DNA methylation in the pathophysiology of VTE during pregnancy.

This study has several limitations. The first is the small sample size, which makes it difficult to perform further detailed analyses. However, the present study demonstrated the concept of “DNA methylation changes during pregnancy” and provided insights on these changes. Further studies with more samples are required to present more detailed subgroup analyses. The second limitation is that all pregnant women included in the study were Han Chinese. Further studies on other ethnic groups are required to determine whether racial differences exist. Third, DNA methylation was measured in whole blood, without adjusting for leukocyte proportions. DNA from peripheral blood is a mixture of genetic substrates from various leukocyte subtypes, and variations in leukocyte proportions could confound the true epigenetic associations between phenotype and DNA methylation (34). EpiDISH software (R) was used to calculate the cell composition of each sample (Supplementary Table 13) (43). In the literature, most studies have used data on DNA methylation without adjusting for leukocyte proportion (14, 15, 44), which is similar to the present study; this makes comparisons between studies easier. In addition, we focused on dynamic changes during different trimesters, which included changes in leukocyte proportions. However, for mechanistic implications, further studies considering the role of different leukocyte ratios are required. Fourth, although we provided each pregnant woman with diet education at the first prenatal visit and recommended taking 400 to 1,000 µg of folate or folic acid per day, 1,000 mg of calcium per day and 70–90 g of protein per day throughout pregnancy, a diet diary was not maintained in this study. Further investigations of DNA methylation during pregnancy should consider diet and nutrition.

**CONCLUSION**

In conclusion, the present study provides supporting evidence that DNA methylation patterns change in the three trimesters of pregnancy and after delivery.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

This study was approved by the Research Ethics Committee of the National Taiwan University Hospital (NTUH-REC No.: 201907038RINC). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

M-WL was responsible for the data collection and manuscript writing. C-YS and M-HT performed the statistical calculations. Y-YT also helped with the clinical data collection. C-NL provided his patients and planned the study. S-YL conceived the original idea and helped write the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by a grant (109-S4466) from National Taiwan University Hospital.

ACKNOWLEDGMENTS

We acknowledge the technical support provided by the Center for Biotechnology of National Taiwan University.

REFERENCES

1. Tan EK, Tan EL. Alterations in physiology and anatomy during pregnancy. Best Pract Res Clin Obstet Gynaecol. (2013) 27:791–802. doi: 10.1016/j.bpobgyn.2013.08.001
2. Bernstein IM, Ziegler W, Badger GJ. Plasma volume expansion in early pregnancy. Obstet Gynecol. (2001) 97:669–72. doi: 10.1097/00006250-200105000-00005
3. Aghaeepour N, Ganio EA, McIlwain D, Tsai AS, Tingle M, Van Gassen S, et al. An immune clock of human pregnancy. Sci Immunol. (2017) 2: eaan2946. doi: 10.1126/sciimmunol.aan2946
4. Yang F, Zheng Q, Jin L. Dynamic function and composition changes of immune cells during normal and pathological pregnancy at the maternal-fetal interface. Front Immunol. (2019) 10:2317. doi: 10.3389/fimmu.2019.02317
5. Godfrey KM, Costello PM, Lillycrop KA. Development, epigenetics and metabolic programming. Nestle Nutr Inst Workshop Ser. (2016) 85:71–80. doi: 10.1159/000439488
6. Godfrey KM, Lillycrop KA, Burdge GC, Gluckman PD, Hanson MA. Non-imprinted epigenetics in fetal and postnatal development and growth. Nestle Nutr Inst Workshop Ser. (2013) 71:57–63. doi: 10.1159/000342552
7. Goyal D, Limesand SW, Goyal R. Epigenetic responses and the developmental origins of health and disease. J Endocrinol. (2019) 242:T105–19. doi: 10.1530/JOE-19-0009
8. Dias S, Adam S, Van Wyk N, Rheeders P, Louw J, Pheiffer C. Global DNA methylation profiling in peripheral blood cells of South African women with gestational diabetes mellitus. Biomarkers. (2019) 24:225–31. doi: 10.1080/1354750X.2018.1539770
9. Hong X, Sherwood B, Ladd-Acosta C, Peng S, Ji H, Hao K, et al. Genome-wide DNA methylation associations with spontaneous preterm birth in US blacks: findings in maternal and cord blood samples. Epigenetics. (2018) 13:163–72. doi: 10.1080/15592294.2017.1287654
10. Liu X, Ye Y, Chen Y, Li X, Feng B, Cao G, et al. Effects of prenatal exposure to air particulate matter on the risk of preterm birth and roles of maternal and cord blood LINE-1 methylation: a birth cohort study in Guangzhou, China. Environ Int. (2019) 133:105177. doi: 10.1016/j.envint.2019.105177
11. Mousa AA, Cappello RE, Estrada-Gutierrez G, Shukla J, Romero R, Strauss JF, et al. Preeclampsia is associated with alterations in DNA methylation of genes involved in collagen metabolism. Am J Pathol. (2012) 181:1455–63. doi: 10.1016/j.ajpath.2012.06.019
12. Qi YH, Teng F, Zhou Q, Liu YX, Wu JF, Yu SS, et al. Unmethylated-maspin DNA in maternal plasma is associated with severe preeclampsia. Acta Obstet Gynecol Scand. (2015) 94:983–8. doi: 10.1111/aogs.12691
13. Tai YY, Lee CN, Kuo CH, Lin MW, Chen KY, Lin SY, et al. Simplifying the screening of gestational diabetes by maternal age plus fasting plasma glucose at first prenatal visit: a prospective cohort study. PLoS ONE. (2020) 15:e0237224. doi: 10.1371/journal.pone.0237224
14. Pauwels S, Duca RC, Devlieger R, Freson K, Strietmans D, Van Herck E, et al. Maternal methyl-group donor intake and global DNA (Hydroxymethyl) modification before and during pregnancy. Nutrients. (2016) 8:474. doi: 10.3390/nu8040474
15. Chen S, Mukherjee N, Janjanam VD, Arshad SH, Kurukulaaratchy RJ, Holloway JW, et al. Consistency and variability of DNA methylation in women during puberty, young adulthood, and pregnancy. Genet Epigenet. (2017) 9:1179237X17721540. doi: 10.1177/1179237X17721540
16. Dias S, Adam S, Rheeders P, Louw J, Pheiffer C. Altered genome-wide DNA methylation in peripheral blood of South African women with gestational diabetes mellitus. Int J Mol Sci. (2019) 20:5828. doi: 10.3390/ijms20235828

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.829915/full#supplementary-material

Supplementary Figure 1 | The principle component analysis (PCA) of the 40 samples to exclude batch effect. Chip ID was shown. X-axis denotes that the first principal component explains the variability around 65% and Y-axis denotes that the second principal component explains the variability around 15.4%.

Supplementary Table 1 | The plate layout of Illumina Human MethylationEPIC BeadChip Array.
Supplementary Table 2 | The identified CpG cites in group 1.
Supplementary Table 3 | The identified CpG cites in group 2.
Supplementary Table 4 | The identified CpG cites in group 3.
Supplementary Table 5 | The identified CpG cites in group 4.
Supplementary Table 6 | The identified CpG cites in group 5.
Supplementary Table 7 | The identified CpG cites in group 6.
Supplementary Table 8 | The identified CpG cites in group 7.
Supplementary Table 9 | The identified CpG cites in group 8.
Supplementary Table 10 | The identified CpG cites in group 9.
Supplementary Table 11 | The 122 CpG sites identified with significantly differentially methylated in pregnancy compared with non-pregnancy groups both in the White et al. and in this study.
Supplementary Table 12 | The 133 CpG sites identified with significantly differentially methylated in pregnancy compared with non-pregnancy groups both in the Gruzieva et al. and in this study.
Supplementary Table 13 | The estimated blood cells ratio in each sample.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.829915/full#supplementary-material

Copyright © 2022 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Lin et al.

DNA Methylation During Pregnancy

Enquilobahri DA, Moore A, Muhie S, Tadesse MG, Lin S, Williams MA. Early pregnancy maternal blood DNA methylation in repeat pregnancies and change in gestational diabetes mellitus status—a pilot study. *Reprod Sci.* (2015) 22:904–10. doi: 10.1177/1933719115570903

Kang J, Lee CN, Li HY, Hsu KH, Lin SY. Genome-wide DNA methylation variation in maternal and cord blood of gestational diabetes population. *Diabetes Res Clin Pract.* (2017) 132:127–36. doi: 10.1016/j.diabres.2017.07.034

Wu P, Farrell WE, Haworth KE, Emes RD, Kitchen MO, Glossop JR, et al. Maternal genome-wide DNA methylation profiling in gestational diabetes shows distinctive disease-associated changes relative to matched healthy pregnancies. *Epidemiol. (2018)* 13:122–8. doi: 10.1080/15592294.2016.1166321

Burris HH, Rifa-Shiman SL, Baccarelli A, Tarantini L, Boeke CE, Kleinman K, et al. Associations of LINE-1 DNA methylation with preterm birth in a prospective cohort study. *J Dev Orig Health Dis.* (2012) 3:173–81. doi: 10.1017/S2040174412000104

Paredes SE, Connelly KN, Kilaru V, Menon R, Smith AK. DNA methylation provides insight into intergenerational risk for preterm birth in African Americans. *Epidemiol.* (2015) 10:784–92. doi: 10.1080/15592294.2015.1062964

Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, et al. Comparison of beta-value and M-value methods for quantifying methylation levels by microarray analysis. *BMC Bioinformatics.* (2010) 11:587. doi: 10.1186/1471-2105-11-587

Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. *Mol Cell.* (2009) 34:259–69. doi: 10.1016/j.molcel.2009.04.026

Bebington C, Doherty FJ, Fleming SD. The possible biological and reproductive functions of ubiquitin. *Hum Reprod Update.* (2007) 1:702–11. doi: 10.1093/humupd/71.1.102

Luo X, Shi Q, Gu Y, Pan J, Hua M, Liu M, et al. lncRNA pathway involved in premature preterm rupture of membrane (PPROM): an epigenomic approach to study the pathogenesis of reproductive disorders. *PLoS ONE.* (2013) 8:e79897. doi: 10.1371/journal.pone.0079897

Luo X, Pan J, Wang L, Wang P, Zhang M, Liu M, et al. Epigenetic regulation of lncRNA connects ubiquitin-proteasome system with infection-inflammation in preterm births and preterm premature rupture of membranes. *BMC Pregnancy Childbirth.* (2015) 15:35. doi: 10.1186/s12884-015-0460-0

Zhao X, Dong X, Luo X, Pan J, Ju W, Zhang M, et al. Ubiquitin-proteasome-collagen (CUP) pathway in preterm premature rupture of fetal membranes. *Front Pharmacol.* (2017) 8:310. doi: 10.3389/fphar.2017.00310

Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Llurba E, Gris JM. Tumor necrosis factor-alpha and pregnancy: focus on biologics. *An up to date comprehensive review.* *Clin Rev Allergy Immunol.* (2017) 53:40–53. doi: 10.1007/s12512-016-0859-x

Deter RL, Buster JE, Casson PR, Carson SA. Individual growth patterns in the first trimester: evidence for difference in embryonic and fetal growth rates. *Ultrasound Obstet Gynecol.* (1999) 13:90–8. doi: 10.1046/j.1469-0705.1999.13020090.x

Kang J, Lee CN, Li HY, Hsu KH, Wang SH, Lin SY. Association of interleukin-10 methylation levels with gestational diabetes in a Taiwanese population. *Front Genet.* (2018) 9:222. doi: 10.3389/fgene.2018.00222

Kitsios-Tzel S, Tzetis M. Maternal epigenetics and fetal and neonatal growth. *Curr Opin Endocrinol Diabetes Obes.* (2017) 24:43–6. doi: 10.1097/MED.0000000000000305

Argyriak M, Dambudzopovu P, Chatzimeliotou K, Grimbizis GF, Tarlatzis BC, Syrou M, et al. In-utero stress and mode of conception: impact on regulation of imprinted genes, fetal development and future health. *Hum Reprod Update.* (2019) 25:777–801. doi: 10.1093/humupd/dmz025

Drake AJ, McPherson RC, Godfrey KM, Cooper C, Lillicrop KA, Hanson MA, et al. An unbalanced maternal diet in pregnancy associates with offspring epigenetic changes in genes controlling glucocorticoid action and foetal growth. *Clin Endocrinol.* (2012) 77:808–15. doi: 10.1111/j.1365-2265.2012.04453.x

Gruzieva O, Merid SK, Shen S, Mukherjee N, Hedman AM, Almqvist C, et al. DNA methylation trajectories during pregnancy. *Epigenet Insights.* (2019) 12:2516865719867090. doi: 10.1017/2516865719867090

White WM, Brost BC, Sun Z, Rose C, Graici I, Wagner SJ, et al. Normal early pregnancy: a transient state of epigenetic change favoring hypomethylation. *Epidemiol.* (2012) 7:729–34. doi: 10.1161/epi.20388

Smeiw AI, Hedman AM, Chiesa F, Ullumar V, Andolfi E, Pershagen G, et al. Limited association between markers of stress during pregnancy and fetal growth in ‘Born into Life’, a new prospective birth cohort. *Acta Paediatr.* (2018) 107:1003–10. doi: 10.1111/apaa.14246

Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. *Arterioscler Thromb Vasc Biol.* (2012) 32:563–8. doi: 10.1161/ATVBAHA.111.242818

Wang X, Menon AA, Palmer K, Svensson PJ, Sundquist J, Sundquist K. The association between blood-based global DNA methylation and venous thromboembolism. *Semin Thromb Hemost.* (2021) 47:662–8. doi: 10.1055/s-0040-1722271

Rocanin-Arjo A, Dennis J, Suchon P, Aissi D, Truong V, Tregouet DA, et al. Thrombin generation potential and whole-blood DNA methylation. *Thromb Res.* (2015) 135:561–4. doi: 10.1016/j.thromres.2014.12.010

El-Maarri O, Becker T, Junen J, Manzoor SS, Díaz-Lacava A, Schaaw R, et al. Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. *Hum Genet.* (2007) 122:505–14. doi: 10.1007/s00439-007-0430-3

Friso S, Lotto V, Choi SW, Girelli D, Pinotti M, Guarini P, et al. Promoter methylation in coagulation F7 gene influences plasma FVII concentrations and relates to coronary artery disease. *J Med Genet.* (2012) 49:192–9. doi: 10.1136/jmedgenet-2011-100195

Peng Y, Jahroudi N. The NFy transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases. *J Biol Chem.* (2003) 278:8385–94. doi: 10.1074/jbc.M213156200

Zhang SC, Breeze CE, Beck S, Dong D, Zhu T, Ma L, et al. EpiDISH web server: epigenetic dissection of intra-sample heterogeneity with online GUI. *Bioinformatics.* (2019) 35:1950–1951. doi: 10.1093/bioinformatics/btz833

Mansell G, Gorrie-Stone TJ, Bao Y, Kumari M, Schalkwyk LS, Mill J, et al. Guidance for DNA methylation studies: statistical insights from the illumina EPIC array. *BMC Genomics.* (2020) 20:366. doi: 10.1186/s12864-019-5761-7

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lin, Tsai, Shih, Tai, Lee and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.